Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An examination of short-term operating activity ratios reveals several notable trends over the observed period. Generally, a decline in efficiency metrics is apparent, particularly in the earlier part of the period, followed by some stabilization and, in a few cases, modest improvement in more recent quarters. The analysis below details these observations by ratio.
- Inventory Management
- Inventory turnover consistently decreased from 1.27 in March 2022 to a low of 0.64 in September 2024, before showing slight improvement to 0.66 in December 2025. This indicates a lengthening of the time inventory is held, potentially due to slowing sales, increased inventory levels, or a combination of both. Correspondingly, the average inventory processing period increased substantially from 287 days in March 2022 to 582 days in March 2025, before decreasing slightly to 556 days in December 2025. This extended processing period suggests potential challenges in inventory management and demand forecasting.
- Receivables Management
- Receivables turnover exhibited a decreasing trend from 3.41 in March 2022 to 2.27 in September 2024, followed by a slight recovery to 2.50 in December 2025. This suggests a slowing in the rate at which the company collects its receivables. The average receivable collection period increased from 107 days in March 2022 to a peak of 161 days in September 2024, then stabilized around 146 days through December 2025. This lengthening collection period could indicate more lenient credit terms, difficulties in collecting payments, or a shift in the customer base.
- Payables Management
- Payables turnover demonstrated volatility. It decreased from 5.39 in March 2022 to 2.50 in September 2024, then showed some fluctuation, ending at 2.24 in December 2025. The average payables payment period increased from 68 days in March 2022 to 163 days in December 2025, indicating the company is taking longer to pay its suppliers. This could be a strategic decision to manage cash flow, but prolonged increases may strain supplier relationships.
- Overall Operating Cycle & Cash Conversion Cycle
- The operating cycle lengthened considerably from 394 days in March 2022 to 734 days in September 2024, before decreasing to 702 days in December 2025. This increase reflects the combined effect of slower inventory turnover and a longer receivable collection period. The cash conversion cycle followed a similar pattern, increasing from 326 days in March 2022 to 586 days in September 2024, and then decreasing to 539 days in December 2025. This indicates a longer time between paying for inventory and receiving cash from sales.
- Working Capital Turnover
- Working capital turnover generally declined from 1.46 in March 2022 to 0.82 in September 2022, and then fluctuated between 0.82 and 1.08 before ending at 1.05 in December 2025. This suggests a decreasing efficiency in utilizing working capital to generate sales. The relatively stable performance in the most recent quarters may indicate a bottoming out of this trend.
In summary, the observed trends suggest a general decrease in operational efficiency over the period, particularly in the management of inventory and receivables. While some stabilization is evident in the most recent quarters, continued monitoring of these ratios is warranted to assess whether these improvements are sustainable and to identify potential areas for operational improvement.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Cost of revenues | |||||||||||||||||||||
| Inventories | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Inventory turnover
= (Cost of revenuesQ4 2025
+ Cost of revenuesQ3 2025
+ Cost of revenuesQ2 2025
+ Cost of revenuesQ1 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Inventory turnover exhibited a consistent downward trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio stood at 1.27, but progressively declined to 0.66 by the end of the analyzed timeframe. While fluctuations occurred, the overall trajectory indicates a lengthening of the inventory conversion cycle.
- Initial Decline (Mar 31, 2022 – Dec 31, 2022)
- A substantial decrease in inventory turnover is evident during this period, falling from 1.27 to 0.65. This suggests a slowing in the rate at which inventory was sold and replenished. The cost of revenues also showed variability, with a significant increase in the final quarter of 2022, potentially contributing to the lower turnover.
- Stabilization and Slight Improvement (Jan 1, 2023 – Sep 30, 2023)
- From the beginning of 2023 through September 2023, the inventory turnover ratio remained relatively stable, fluctuating between 0.67 and 0.72. This indicates a potential leveling off of the previous decline, although it remained significantly lower than the initial value in 2022. Cost of revenues remained relatively consistent during this period.
- Continued Decline and Final Period (Oct 1, 2023 – Dec 31, 2025)
- The ratio experienced a further, albeit more gradual, decline from 0.70 in September 2023 to 0.66 in December 2025. This suggests that the factors contributing to the initial slowdown persisted. Inventories consistently increased throughout this period, while cost of revenues also showed an upward trend, reinforcing the observation of a slower inventory conversion rate.
- Inventory Levels
- Concurrent with the declining inventory turnover, inventory levels demonstrated a consistent upward trend. Starting at US$1,991,500 in thousands in March 2022, inventories rose to US$3,200,800 in thousands by December 2025. This increase in inventory holdings, coupled with the decreasing turnover, suggests a potential build-up of stock that is taking longer to sell.
The observed trend warrants further investigation to determine the underlying causes. Potential factors could include changes in product mix, increased competition, shifts in demand, or inefficiencies in supply chain management. A sustained low inventory turnover ratio may indicate increased holding costs, potential obsolescence, and reduced profitability.
Receivables Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Receivables turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Accounts receivable, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio for the analyzed period demonstrates a generally declining trend, with some fluctuations. Initially, the ratio decreased from 3.41 to 2.28 between March 2022 and December 2022. Subsequently, the ratio exhibited relative stability, fluctuating between 2.27 and 2.53 from March 2023 through September 2025. A slight decrease to 2.50 is observed in the final period, December 2025.
- Overall Trend
- The receivables turnover ratio experienced a significant decrease in the first portion of the analyzed period, followed by a period of relative stability. The initial decline suggests a lengthening of the collection period for accounts receivable. The subsequent stabilization indicates that collection efficiency has remained relatively consistent, despite the initial downturn.
- Initial Decline (Mar 31, 2022 – Dec 31, 2022)
- A notable decrease in the receivables turnover ratio is evident during this timeframe. This suggests that, relative to revenues, the level of outstanding accounts receivable increased. This could be attributable to changes in credit policies, slower customer payments, or a shift in the customer mix towards those with longer payment terms. The ratio decreased by approximately 33.4% over this period.
- Period of Stability (Mar 31, 2023 – Sep 30, 2025)
- From March 2023 through September 2025, the ratio remained within a narrow range. This suggests that the company has maintained a consistent level of efficiency in converting receivables into cash. While there are minor fluctuations, they do not indicate a significant change in the collection process. The ratio fluctuated between 2.27 and 2.53 during this period.
- Recent Performance (Dec 31, 2024 – Dec 31, 2025)
- The most recent two periods show a slight decrease in the ratio, moving from 2.53 to 2.50. While minimal, this could warrant further investigation to determine if it signals the beginning of a new downward trend or is simply a temporary fluctuation. The decrease is less than 1%.
In conclusion, the receivables turnover ratio indicates an initial weakening in collection efficiency followed by a period of relative stability. The recent slight decrease suggests a need for continued monitoring to ensure that collection processes remain effective.
Payables Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Cost of revenues | |||||||||||||||||||||
| Accounts payable | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Payables turnover
= (Cost of revenuesQ4 2025
+ Cost of revenuesQ3 2025
+ Cost of revenuesQ2 2025
+ Cost of revenuesQ1 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The accounts payable turnover ratio exhibits considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates a declining trend, followed by periods of relative stability and subsequent decreases. A detailed examination reveals specific patterns and potential areas of interest.
- Initial Decline (Mar 31, 2022 – Dec 31, 2022)
- The payables turnover ratio decreased from 5.39 in March 2022 to 2.65 by December 2022. This decline suggests a lengthening of the time it takes to pay suppliers, potentially due to increased negotiating power with vendors, a shift in procurement strategies, or a deliberate attempt to manage cash flow. The cost of revenues also fluctuated during this period, but the decrease in the turnover ratio indicates that the growth in accounts payable outpaced the changes in cost of revenues.
- Stabilization and Subsequent Fluctuation (Mar 31, 2023 – Dec 31, 2023)
- From March 2023 to December 2023, the ratio experienced some volatility, ranging from 2.69 to 2.99. While not a substantial increase, this suggests a partial reversal of the previous decline. However, the ratio remained below the levels observed in the first quarter of 2022. Cost of revenues also showed fluctuations, but the payables turnover remained relatively contained.
- Further Decline (Mar 31, 2024 – Dec 31, 2025)
- The period from March 2024 to December 2025 shows a renewed downward trend, with the ratio falling to 2.24 by the end of 2025. This represents the lowest point in the observed period. Accounts payable increased significantly, reaching 939,000 in December 2025, while the cost of revenues also increased, but not at a rate sufficient to maintain the turnover ratio. This suggests a further lengthening of the payment cycle and potentially increasing reliance on supplier credit.
Overall, the accounts payable turnover ratio demonstrates a general tendency towards decline over the analyzed timeframe. While short-term fluctuations occur, the overarching pattern indicates a slower rate of paying suppliers. This trend warrants further investigation to determine the underlying causes and potential implications for the company’s financial health and supplier relationships.
Working Capital Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||
| Working capital | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Working capital turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio demonstrates a generally declining trend over the observed period, with some fluctuations. Initially, the ratio stood at 1.46, indicating a relatively efficient use of working capital to generate revenue. However, subsequent quarters reveal a consistent decrease, reaching a low of 0.82 before exhibiting a modest recovery towards the end of the period.
- Overall Trend
- From March 2022 to December 2022, the working capital turnover ratio decreased from 1.46 to 0.96, representing a substantial reduction in efficiency. This suggests that the company was utilizing its working capital less effectively to drive sales during this timeframe. A slight recovery is observed in the latter part of the period, but the ratio generally remains below the initial value.
- Fluctuations and Recovery
- Following the low of 0.82 in September 2022, the ratio experienced some volatility. It increased to 0.97 by December 2024, indicating a potential stabilization or improvement in working capital management. However, this improvement was not sustained, with a slight decrease to 1.05 by December 2025. The ratio shows a slight increase from 0.86 in March 2023 to 1.05 in December 2025.
- Recent Performance
- The most recent quarters (March 2024 through June 2025) show a relatively stable ratio, fluctuating between 0.86 and 1.08. This suggests a period of consolidation in working capital management practices. The final reported value of 1.05 indicates a modest level of efficiency in utilizing working capital to generate revenue.
The observed trend warrants further investigation to understand the underlying factors contributing to the decline in working capital turnover. Potential causes could include increases in working capital components (inventory, receivables, or payables) without a corresponding increase in revenue, or a shift in business strategy impacting operational efficiency. The recent stabilization suggests that corrective measures may be having an effect, but continued monitoring is recommended.
Average Inventory Processing Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average inventory processing period exhibited a generally increasing trend over the observed timeframe, beginning in March 2022 and continuing through September 2025. While fluctuations occurred, the overall movement indicates a lengthening of the time required to convert inventory into finished goods and ultimately, sales.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The average inventory processing period began at 287 days in March 2022. A substantial increase was observed throughout the year, reaching 562 days by December 2022. This represents a significant lengthening of the inventory cycle during this period.
- Stabilization and Fluctuation (Mar 31, 2023 – Dec 31, 2024)
- Following the peak in December 2022, the period experienced a slight decrease to 549 days in March 2023, followed by relative stabilization between 508 and 573 days through December 2024. While not consistently increasing, the values remained elevated compared to the initial period in 2022, indicating a sustained longer inventory cycle.
- Recent Trend (Mar 31, 2025 – Dec 31, 2025)
- The period showed a slight increase to 582 days in March 2025, followed by a minor decrease to 556 days by December 2025. This suggests a potential stabilization or a very gradual decline in the inventory processing period, but remains at a considerably higher level than the initial observation in March 2022.
- Correlation with Inventory Turnover
- The observed trend in the average inventory processing period is inversely related to the inventory turnover ratio. As the inventory turnover ratio decreased from 1.27 in March 2022 to 0.66 in December 2025, the average inventory processing period increased. This confirms the expected relationship: a lower turnover rate corresponds to a longer time to process inventory.
In summary, the average inventory processing period has generally increased over the analyzed period, indicating a slower movement of inventory. The most significant increase occurred between March 2022 and December 2022, with subsequent periods showing stabilization at a higher level. The inverse relationship with the inventory turnover ratio reinforces this observation.
Average Receivable Collection Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited a generally increasing trend from March 31, 2022, through December 31, 2023, before stabilizing and showing some fluctuation in the subsequent periods. This indicates a lengthening in the time required to collect receivables over much of the analyzed timeframe.
- Overall Trend
- Beginning at 107 days in March 2022, the average collection period steadily increased, peaking at 160 days by December 2022 and remaining elevated at 158 days by December 2023. From March 2024 onwards, the period fluctuated between 144 and 161 days, suggesting a potential plateau or stabilization, though with some variability.
- Period of Significant Increase
- The most pronounced increase occurred between March 31, 2022, and December 31, 2022, representing an increase of 53 days. This suggests a potential shift in credit terms, customer payment behavior, or collection efforts during that period.
- Recent Performance (2024-2025)
- From March 2024 through December 2025, the average collection period remained relatively stable, oscillating within a range of 144 to 161 days. The most recent value, 146 days as of December 31, 2025, is slightly lower than the peak observed in late 2022 and 2023, but still considerably higher than the period observed in early 2022.
The observed trends suggest a potential need to investigate the factors contributing to the lengthening collection period, particularly the changes occurring in 2022. While the period has stabilized more recently, continued monitoring is warranted to ensure efficient cash flow management.
Operating Cycle
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle for the analyzed period demonstrates a generally increasing trend, with notable fluctuations. Both components contributing to the operating cycle – average inventory processing period and average receivable collection period – exhibit lengthening durations over the observed timeframe.
- Average Inventory Processing Period
- The average inventory processing period shows a consistent upward trajectory, beginning at 287 days in March 2022 and reaching 582 days by March 2025. While there are minor quarterly variations, the overall trend indicates a significant increase in the time required to convert inventory into finished goods and make them available for sale. A slight decrease is observed in the final period, ending at 556 days in December 2025, but remains substantially higher than the initial value. The most substantial increase occurred between March 2022 and December 2022.
- Average Receivable Collection Period
- The average receivable collection period also displays an increasing trend, though less pronounced than that of the inventory processing period. Starting at 107 days in March 2022, it rises to 161 days by September 2024, before decreasing slightly to 146 days by December 2025. The period experienced its highest values between September 2023 and September 2024. The increase suggests a lengthening of the time it takes to collect payments from customers.
- Operating Cycle
- The operating cycle, calculated as the sum of the inventory processing period and the receivable collection period, reflects the combined effect of these trends. It increases from 394 days in March 2022 to 734 days in September 2024, before decreasing to 702 days in December 2025. The peak value of 734 days indicates a substantial extension in the time required to complete the full cycle of inventory purchase, production, sale, and cash collection. The overall trend suggests a growing inefficiency in the company’s short-term operating activities. The period between March 2022 and September 2024 shows the most significant increase.
The consistent lengthening of both the inventory processing and receivable collection periods contributes to the extended operating cycle. This could indicate potential issues with inventory management, production efficiency, credit policies, or collection efforts. Further investigation into the underlying causes of these trends is warranted.
Average Payables Payment Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. An initial increase is noted, followed by periods of both increase and decrease, ultimately concluding with a period longer than any previously recorded.
- Initial Trend (Mar 31, 2022 – Dec 31, 2022)
- The average payables payment period increased from 68 days in March 2022 to a peak of 138 days by December 2022. This suggests a lengthening in the time taken to settle obligations to suppliers during this timeframe. This lengthening coincides with a decrease in payables turnover.
- Fluctuation and Stabilization (Mar 31, 2023 – Jun 30, 2024)
- Following the peak, the period decreased to 116 days by June 2023, before increasing again to 137 days by March 2024. A subsequent decrease to 110 days was observed by June 2024. This period demonstrates volatility, with no clear sustained trend. Payables turnover also fluctuated during this period.
- Recent Trend (Sep 30, 2024 – Dec 31, 2025)
- From September 2024, the average payables payment period began a sustained increase, reaching 146 days by December 2024 and culminating in 163 days by December 2025. This represents the longest payment period recorded within the analyzed timeframe. This increase is coupled with a continued decline in payables turnover.
- Overall Observation
- The overall trend indicates increasing payment times to suppliers in the latter portion of the analyzed period. While earlier periods showed fluctuation, the final measurements suggest a potential shift in payment practices or a change in supplier terms. The decreasing payables turnover ratio supports this observation, indicating a slower rate of paying off accounts payable.
Cash Conversion Cycle
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity, as measured by the cash conversion cycle and its components, exhibits notable fluctuations over the observed period. Generally, the cycle length increased from early 2022 through late 2023, before showing some signs of stabilization and slight decrease in the most recent periods.
- Average Inventory Processing Period
- The average time to process inventory demonstrated a consistent upward trend from 287 days in March 2022 to a peak of 582 days in March 2025. This indicates a lengthening of the time required to convert raw materials into finished goods and ultimately sell them. While there were quarterly variations, the overall trajectory points to increasing inventory holding periods. The period fluctuated between 556 and 573 days in the last four quarters.
- Average Receivable Collection Period
- The average number of days to collect receivables also increased from 107 days in March 2022 to 161 days in September 2024, before stabilizing around 146 days in the final four quarters. This suggests a lengthening of the time it takes to convert sales into cash. The increase implies a potential need to review credit policies or collection efforts. The period remained relatively stable between 144 and 161 days from March 2024 through December 2025.
- Average Payables Payment Period
- The average time to pay suppliers showed a more volatile pattern. It increased from 68 days in March 2022 to 163 days in December 2025, with a significant jump between March 2022 and December 2022. This suggests a lengthening of payment terms taken from suppliers. The period experienced a decrease from 146 days in December 2024 to 163 days in December 2025.
- Cash Conversion Cycle
- The cash conversion cycle, representing the total time funds are tied up in operations, increased substantially from 326 days in March 2022 to a high of 640 days in September 2024. This indicates a growing gap between paying for inventory and collecting cash from sales. The cycle decreased to 539 days by December 2025, suggesting some improvement in working capital management, but remains significantly higher than the initial value. The increase was primarily driven by the lengthening inventory and receivable periods, partially offset by changes in the payables period.
Overall, the trends suggest a growing inefficiency in working capital management, particularly in inventory and receivables, although recent periods show some potential for stabilization. The lengthening cash conversion cycle could indicate a need for strategic review of operational processes and financial policies.